AIM
AMRX icon

Advantage Investment Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Advantage Investment Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$1K Hold
200
– – ﹤0.01% 878
2019
Q2 		$1K Hold
200
– – ﹤0.01% 892
2019
Q1 		$3K Hold
200
– – ﹤0.01% 822
2018
Q4 		$3K Buy
+200
New +$3.6K ﹤0.01% 833

Other funds holding AMRX

FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Advantage Investment Management's AMRX Position: Q3 2019 in Review

Advantage Investment Management held its Amneal Pharmaceuticals (AMRX) position steady in Q3 2019 at 200 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #878.

Advantage Investment Management first reported a position in AMRX in Q4 2018 and has held it in 4 quarters since. The position peaked at $3K in Q1 2019. 121 funds tracked by Wall St. Rank hold AMRX as of Q3 2019.

  • Advantage Investment Management held 200 shares of Amneal Pharmaceuticals worth $1K as of Q3 2019.
  • Advantage Investment Management left its Amneal Pharmaceuticals share count unchanged in Q3 2019.
  • Amneal Pharmaceuticals made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #878 holding.
  • Advantage Investment Management first reported a position in Amneal Pharmaceuticals in Q4 2018 and has held it in 4 quarters since.
  • Advantage Investment Management's Amneal Pharmaceuticals position peaked at $3K in Q1 2019.
  • 121 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.